corticosteroid (potency)
Last reviewed 09/2021
Corticosteroids in general:
Equivalent anti-inflammatory doses of different oral corticosteroids |
This table takes no account of mineralocorticoid effects, nor does it take account of variations in duration of action Prednisolone 5mg is equivalent to betamethasone 750 mcg is equivalent to cortisone acetate 25 mg is equivalent to dexamethasone 750 mcg is equivalent to deflazacort 6mg is equivalent to hydrocortisone 20mg is equivalent to methylprednisolone 4mg is equivalent to traimacinolone 4mg |
Note that mineralocorticoid side effects are most marked with fludrocortisone, but are significant with cortisone, hydrocortisone, corticotropin, and tetracosactide (tetracosacrtin). Minerlacorticoid actions are negligible with the high potency glucocorticoids, betamethasone and dexamethasone, and occur only slightly with methylprednisolone, prednisolone, triamcinolone.
Topical corticosteroids:
The potency of topical corticosteroids is determined by
- the extent to which it inhibits inflammation (2)
- the specific modification (esterification) of the steroid molecule e.g. - hydrocortisone (acetate) 1% is mild but hydrocortisone butyrate 0.1% is a potent preparation (3)
- the formulation
- presence of other ingredients such as urea or salicylic acid which may increase the absorption of the drug (4)
- occlusive dressings or increasing hydration of the stratum corneum (increases steroid absorption) (5)
POTENCY EXAMPLES
- mild
- hydrocortisone 0.1-1%
- moderate
- clobetasone butyrate 0.05%
-
potent
- hydrocortisone butyrate
- betamethasone valerate
0.1%
- very potent
- clobetasol propionate 0.05%
The respective summary of product characteristics must be checked before prescribing any of the drugs described.
Reference:
- (1) BNF 6.3.2 and BNF 13.4
- (2) National Institute for Health and Clinical Excellence (NICE) 2004. Frequency of application of topical corticosteroids for atopic eczema
- (3) National Institute for Health and Clinical Excellence (NICE) 2007. Atopic eczema in childrenmanagement of atopic eczema in children from birth up to the age of 12
- (4) MeReC. Using topical corticosteroids in general practice. MeReC Bulletin 1999;10(6), 21-24
- (5) Tadicherla S et al. Topical corticosteroids in dermatology. J Drugs Dermatol. 2009;8(12):1093-105